Patients with severe kidney disease or end-stage renal disease may not be appropriate candidates for this therapy, particularly if they have significant fluid retention or are prone to dehydration
[2] Es importante destacar que, hasta la fecha, no existe ningn parche transdrmico de GLP-1 aprobado por la FDA para uso clnico en Estados Unidos
With Hims, the higher ongoing monthly spend buys more flexibility because the patient is not locked into a long prepaid term
In addition, because of differences in baseline characteristics between the groups, the analysis was performed post hoc with age, sex, and log(weight) as explanatory variables
a , Structures of agonist-bound GLP-1R
Michaowicz J, Wuka A, Cyrkler M, Maczak A, Siciska P, Mokra K